Intravesical therapy of superficial bladder cancer

Critical Reviews in Oncology/Hematology

Volumn 47, Issue 2, 2003, Pages 109-126

  Malmström, Per Uno ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Bacillus Calmette Guerin; Bladder carcinoma; Intravesical therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; BROPIRIMINE; CACTINOMYCIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOGLUCID; FLUOROURACIL; GEMCITABINE; IMMUNOGLOBULIN G ANTIBODY; INTERFERON; MANNITYL 1,6 DIMESYLATE; MELPHALAN; METHOTREXATE; MITOMYCIN C; PACLITAXEL; PODOPHYLLIN; PROTEIN P53; RECOMBINANT ALPHA INTERFERON; SILVER NITRATE; SURAMIN; TAMOXIFEN; THIOTEPA; TRICHLOROACETIC ACID; TUMOR MARKER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALRUBICIN; VERAPAMIL; VINCRISTINE;

ALLERGIC REACTION; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLADDER CANCER; BLADDER IRRITATION; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CANCER SURGERY; CHEMICAL CYSTITIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOTOXICITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG CONJUGATION; DRUG DIFFUSION; DRUG EFFICACY; DRUG INDICATION; DRUG PENETRATION; DRUG RETENTION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG URINE LEVEL; FLU LIKE SYNDROME; GENE THERAPY; GENE TRANSFER; HUMAN; LIPID SOLUBILITY; MAINTENANCE THERAPY; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE; PHYSICAL CHEMISTRY; PROGNOSIS; RASH; RESIDUAL URINE; REVIEW; SKIN MANIFESTATION; SUPERFICIAL CANCER; TOXICITY; TRANSURETHRAL RESECTION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; URINE PH;

EID: 0042626442     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00075-1     Document Type: Review

References (139)

1. Malmström P.U., Busch C., Norlen B.J. Recurrence, progression, and survival in bladder cancer: a retrospective analysis of 232 patients with greater than or equal to 5-year follow-up. Scand. J. Urol. Nephrol. 21:1987;185-195.
2. Akaza H., Kurth K.H., Hinotsu S., et al. Intravesicle chemotherapy and immunotherapy for superficial tumors: basic mechanism of action and future direction. Urol. Oncol. 4:1998;121-129.
3. Klan R., Loy V., Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J. Urol. 146:1991;316.
4. Page B.H., Levison V.B., Curwen M.P. The site of recurrence of noninfiltrating bladder tumors. Br. J. Urol. 50:1978;237.
5. Oosterlinck W., Kurth K.H., Schroder F., et al. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single Ta, T1 papillary carcinoma of the bladder. J. Urol. 149:1993;749-752.
6. Cookson M.S., Sarosdy M.F. Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy. J. Urol. 148:1992;797.
7. Freeman J.A., Esrig D.E., Stein J.P., et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer. 76:1995;833.
8. Wolf H., Melsen F., Pederson S.E., Nielson K.T. Natural history of carcinoma in situ of the urinary bladder. Scand. J. Urol. Nephrol. 157:1994;147.
9. Soloway M.S. Rationale for intensive intravesical chemotherapy for superficial bladder cancer. J. Urol. 123:1980;461.
10. Badalament R.A., Farah R.N. Treatment of superficial bladder cancer with intravesical chemotherapy. Semin. Surg. Oncol. 13:1997;335-341.
11. Lamm D.L. Long term results of intravesical therapy for superficial bladder cancer (Review). Urol. Clin. North Am. 19:1992;573.
12. Schmittgen T.D., Au J.L., Wientjes M.G., et al. Cultured human bladder tumors for pharmacodynamic studies. J. Urol. 145:1991;203.
13. Wientjes M.G., Dalton J.T., Badalament R.A., et al. A method to study drug concentration-depth profiles in tissues: mitomycin C in dog bladder wall. Pharm. Res. 8:1991;168.
14. Schmittgen T.D., Wientjes M.G., Badalament R.A., Au J.L. Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res. 51:1991;3849.
15. Wientjes M.G., Dalton J.T., Badalment R.A., et al. Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res. 51:1991;4347.
16. Dalton J.T., Wientjes M.G., Badalament R.A., et al. Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res. 51:1991;5144-5152.
17. Wientjes M.G., Badalament R.A., Au J.L. Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother. Pharmacol. 32:1993;255-262.
18. Wientjes M.G., Badalament R.A., Wang R.C., et al. Penetration of mitomycin C in human bladder. Cancer Res. 53:1993;3314.
19. Schmidbauer C.P., Porpaczy P., Georgeopoulos A., et al. Absorption of doxorubicin-hydrochloride and mitomycin C after instillation into noninfected and infected bladders of dogs. J. Urol. 131:1984;818-821.
20. Dedrick R.L., Flessner M.F., Collins J.M., Schultz J.S. Is the peritoneum a membrane. ASAIO J. 5:1982;1.
21. Flessner M.F., Dedrick R.L., Schultz J.S. A distributive model of peritoneal-plasma transport: analysis of experimental data in the rat. Am. J. Physiol. 248:1985;F413.
22. Wientjes M.G., Badalament R.A., Au J.L. Penetration of intravesical doxorubicin in human bladders. Cancer Chemother. Pharmacol. 37:1996;539-546.
23. Groos E., Masters J.R. Intravesical chemotherapy: studies on the relationship between osmolality and cytotoxicity. J. Urol. 136:1986;399-402.
24. Walker M.C., Masters J.R., Parris C.N., Hepburn P.J., English P.J. Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity. Urol. Res. 14:1986;137-140.
25. Eksborg S., Nillson S., Edsmyr F. Intravesical instillation of adriamycin; a model for standardization of the chemotherapy. Eur. Urol. 6:1980;218-220.
26. Masters J.R., McDermott B.J., Harland S., Bibby M.C., Loadman P.M. ThioTEPA pharmacokinetics during intravesical chemotherapy: the influence of dose and volume of instillate on systemic uptake and dose rate to the tumour. Cancer Chemother. Pharmacol. 38:1996;59-64.
27. Tarkington M., Sommers C.L., Gelmann E.P., Tefft M.C., Lynch J.H. The effect of pH on the in vitro colony-forming ability of transitional cell carcinoma cells treated with various chemotherapeutic agents: implications for in vivo therapy. J. Urol. 147:1992;511.
28. Jauhiainen K., Kangas L., Nieminen A.L., Kapyla H., Alfthan O. Optimising mitomycin C activity during intravesical instillation. Urol. Res. 11:1983;59-62.
29. Yen W.C., Schmittgen T., Au J.L. Different pH dependency of mitomycin C activity in monolayer and three-dimensional cultures. Pharm. Res. 13:1996;1887-1891.
30. De Bruijn E.A., Sleeboom H.P., van Helsdingen P.J., van Oosterom A.T., Tjaden U.R., Maes R.A. Pharmacodynamics and pharmacokinetics of intravesical mitomycin C upon different dwelling times. Int. J. Cancer. 51:1992;359-364.
31. Heney N.M., Koontz W.W., Barton B., et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1, and Tis transitional cell carcinoma of the bladder: a phase III prospective randomized study. J. Urol. 140:1988;1390.
32. Au J.L., Badalament R.A., Wientjes M.G., et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J. Natl. Cancer Inst. 93:2001;597-604.
33. Parmar M.K., Freedrnan L.S., Hargreave T.B., Tolly D.A. Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J. Urol. 142:1989;284.
34. Jones H.C., Swinney J. Thiotepa in the treatment of tumors of the bladder. Lancet. 2:1961;615.
35. Soloway M.S., Ford K.S. Thiotepa induced myelosupression; a review of 670 bladder instillations. J. Urol. 130:1983;889.
36. Crooke S.T. Mitomycin C: an overview. Carter S.K., Crooke S.T. Mitomycin C Current Status and New Developments. 1979;1-4 Academic Press, New York.
37. Thrasher J.B., Crawford E.D. Complications of intravesical chemotherapy. Urol. Clin. North Am. 19:1992;529.
38. Akaza H., Isaka S., Koiso K., et al. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Cancer Chemother. Pharmacol. 20:1987;S91-S96.
39. Crawford E.D., Mc Kenzic D., Mansson W., et al. Adverse reactions to the intravesical administration of doxorubicin hydrochloride: a report of six cases. J. Urol. 136:1986;668.
40. Burk K., Kurth K.H., Newling D. Epirubicin in treatment and recurrence prophylaxis of patients with superficial bladder cancer. Prog. Clin. Biol. Res. 303:1989;423.
41. Riddle P.R. The management of superficial bladder tumors with intravesical epodyl. Br. J. Urol. 45:1973;84.
42. Robinson M.R.G., Shelly M.B., Richards B., et al. Intravesical epodyl in the management of bladder tumors: combined experiences of the Yorkshire Urological Cancer Research Group. J. Urol. 11:1977;972.
43. Patterson A.L., Greenberg R.E., Weems L., et al. Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer. Urology. 56:2000;232-235.
44. Alexandroff A.B., Jackson A.M., O'Donnell M.A., James K. BCG immunotherapy of bladder cancer: 20 years on. Lancet. 353:1999;1689.
45. Yalcinkaya F., Kamis L., Ozteke O., Gunlusoy B., Yigitbasi O., Unal S. Prospective randomized comparison of intravesikal BCG therapy with standard dose versus low doses in superficial bladder cancer. Int. Urol. Nephrol. 30:1998;41-44.
46. Belldegrun A.S., Franklin J.R., O'Donnell M.A., et al. Superficial bladder cancer: the role of interferon-alpha. J. Urol. 159:1998;1793-1801.
47. Bono A.V., Hall R.R., Denis L., Lovisolo J.A., Sylvester R. Chemoresection in Ta-T1 bladder cancer. Members of the EORTC Genito-Urinary Group. Eur. Urol. 29:1996;385-390.
48. Koontz W.W. Jr, Prout G.R., Smith W., et al. The use of intravesical thiotepa in the management of non-invasive carcinoma of the bladder. J. Urol. 125:1981;307.
49. Ali-el-dein B., el-Baz M., Aly A.N., et al. Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study. J. Urol. 158:(1):1997;68-73.
50. Kurth K., Vijgh W.J.F., Fibo T.K., et al. Phase 1/2 study of intravesical epirubicin in patients with carcinoma in situ of the bladder. J. Urol. 146:1991;1508-1512.
51. Malmström P.U. A randomized comparative dose ranging study of interferon-a and mitomycin-C as an internal control in primary or recurrent superficial transitional cell carcinoma of the bladder. Br. J. Urol. Int. 89:2002;1-11.
52. Kurth K.H., Debruyne F.J., Senge T., et al. Adjuvant chemotherapy of superficial transitional cell carcinoma: an E.O.R.T.C. randomized trail comparing doxorubicin hydrochloride, ethoglucid and TUR-alone. Prog. Clin. Biol. Res. 1856:1985;135-142.
53. Huland H., Otto U. Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients. Eur. Urol. 9:1983;84-86.
54. Niijima T., Koiso K., Akaza H. Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother. Pharmacol. 11:(Suppl.):1983;S79-S82.
55. Akaza H., Isaka S., Koiso K., et al. Comparative analysis of short-term and long-term prophylactic intravesical chemotherapy of superficial bladder cancer. Prospective, randomized, controlled studies of the Japanese Urological Cancer Research Group. Cancer Chemother. Pharmacol. 20:(Suppl.):1987;S91-S96.
56. Tolley D.A., Hargreave T.B., Smith P.H., et al. Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). Br. Med. J. (Clin. Res. Ed.). 296:(6639):1988;1759-1761.
57. Kim H.H., Lee C. Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor. J. Urol. 141:1989;1337-1339. discussion 1339-40.
58. Rubben H., Graf-Dobberstein C., Ostwald R., et al. Prospective randomized study of adjuvant therapy after complete resection of superficial bladder cancer; mitomycin C vs. BCG Connaught vs. TUR alone. deKernion J.B., Mazema E. Immunotherapy of Urological Tumors. 1990;27-36 Churchill Livingstone, New York.
59. Minervini R., Felipetto R., Viganoa L., Pampaloni S., Fiorentini L. Recurrences and progressions of superficial bladder cancer following longterm intravesical prophylactic therapy with mitomycin C instillation: 48 months follow-up. Urol. Int. 56:1996;234-237.
60. Burnand K.G., Boyd P.J., Mayo M.E., Shuttleworth K.E., Lloyd-Davies R.W. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br. J. Urol. 48:1976;55-59.
61. Byar D., Blackard C. Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage 1 bladder cancer. Urology. 10:1977;556-618.
62. Nocks B.N., Nieh P.T., Prout G.R. Jr. A longitudinal study of patients with superficial bladder carcinoma successfully treated with weekly intravesical thio-tepa. J. Urol. 122:1979;27-29.
63. Asahi T., Matsumura Y., Tanahashi T., et al. The effects of intravesical instillation of Thio-Tepa on the recurrence rate of bladder tumors. Acta Med. Okayama. 34:1980;43-49.
64. Koontz W.W. Jr, Prout G.R. Jr, Smith W., Frable W.J., Minnis J.E. The use of intravesical thio-tepa in the management of non-invasive carcinoma of the bladder. J. Urol. 125:1981;307-312.
65. Schulman C.C., Robinson M., Denis L., et al. Prophylactic chemotherapy of superficial transitional bladder carcinoma. An EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. Eur. Urol. 8:1982;207-212.
66. Zincke H., Utz D.C., Taylor W.F., Myers R.P., Leary F.J. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J. Urol. 129:1983;505-509.
67. Prout G.R. Jr, Koontz W.W. Jr, Coombs L.J., Hawkins I.R., Friedell G.H. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa. J. Urol. 130:1983;677-680.
68. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer, Br J Urol 1985;57:680-5.
69. Zincke H., Utz D.C., Taylor W.F., Myers R.P., Leary F.J. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J. Urol. 129:1983;505-509.
70. Rubben H., Lutzeyer W., Fischer N., Deutz F., Lagrange W., Giani G. Natural history and treatment of low and high risk superficial bladder tumors. J. Urol. 139:1988;283-285.
71. Akaza H., Koiso K., Kotake T., et al. Long-term results of intravesical chemoprophylaxis of superficial bladder cancer: experience of the Japanese Urological Cancer Research Group for Adriamycin. Cancer Chemother. Pharmacol. 30:(Suppl.):1992;S15-S20.
72. Pawinski A., Sylvester R., Kurth K.H., et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J. Urol. 156:1996;1934-1940.
73. Bouffioux C., Denis L., Oosterlinck W., et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of an European Organisation for Research on Treatment of Cancer randomized trial comparing intravesical instillations of thiotepa, doxorubicin, and cisplatin. J. Urol. 148:1992;297.
74. Huland H., Kloppel G., Feddersen I., Otto U., Brachmann W., Hubmann H., et al. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients. J. Urol. 144:1990;68-71.
75. Buffioux C., Kurth K.H., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of two European Organization for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short term versus long term treatment. European Organization for Research and Treatment of Cancer Genitourinary Group. J. Urol. 153:1995;934-941.
76. Zinke H., Benson R.C. Jr, Hilton J.F., et al. Intravesical thiotepa and mitomycin C treatment immediately after transurethral resection and later for superficial (stages Ta and Tis) bladder cancer: a prospective, randomized, stratified study with crossover design. J. Urol. 134:1985;1110.
77. Bonfante V., Villani F., Bonnadonna G. Toxic and therapeutic activity of 4′ epidoxo-rubicin. Tumori. 68:1982;105.
78. Abrams P.H., Choa R.G., Gaches C.G., et al. A controlled trial of single dose intravesical adriamycin in superficial bladder tumors. Br. J. Urol. 53:(6):1981;585-587.
79. Burnand K.G., Mayo M.E., Shuttleworth K.E., et al. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br. J. Urol. 48:1976;55-59.
80. Tolley D.A., Parmar M.K., Grigor K.M., et al. The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J. Urol. 155:1996;1233-1238.
81. Ali-el-Dein B., Nabeeh A., el-Baz M., Shamaa S., Ashamallah A. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br. J. Urol. 79:1997;731-735.
82. Flamm J. Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer. Eur. Urol. 17:1990;119-124.
83. Okamura K., Kinukawa T., Tsumura Y., Otani T., Itoh H., Kobayashi H., et al. A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur. Urol. 33:1998;285-288.
84. Badalament R.A., Herr H.W., Wong G.Y., et al. A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancer. J. Clin. Oncol. 5:1987;441-449.
85. Hudson M.A., Ratliff T.L., Gillen D.P., Haaff E.O., Dresner S.M., Catalona W.J. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J. Urol. 138:1987;295-298.
86. Palou J., Laguna P., Millan-Rodriguez F., Hall R.R., Salvador-Bayarri J., Vicente-Rodriguez J. Control group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors. J. Urol. 165:2001;1488-1491.
87. Lamm D.L., Blumenstein B.A., Crissman J.D., et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J. Urol. 163:2000;1124-1129.
88. Nseyo U.O. Immunotherapy of bladder cancer. Semin. Surg. Oncol. 13:1997;342.
89. Lamm D.L., Riggs D.R., Traynelis C.L., et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J. Urol. 153:1995;1444-1450.
90. Krege S., Giani G., Meyer R., et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer; transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics [see comments]. J. Urol. 156:1996;962.
91. Vegt P.D., Witjes J.A., Witjes W.P.J., et al. A randomized study of intravesical mitomycin C, Bacille Calmette-Guerin Tice and Bacille Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J. Urol. 153:1995;929.
92. Rintala E., Jauhianien K., Alfthan O., et al. Intravesical chemotherapy (MMC) versus immunotherapy (BCG) in superficial bladder cancer. Eur. Urol. 20:1991;19.
93. Malmström P.U., Wijkström H., Lundholm C., Wester K., Busch C. Norlen 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. Br. J. Urol. 161:1999;1124-1127.
94. Witjes J.A., vd Meijden A.P., Sylvester L.C., Debruyne F.M., van Aubel A., Witjes W.P. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology. 52:1998;403-410.
95. Lamm D.L. BCG in perspective: advances in the treatment of superficial bladder cancer. Eur. Urol. 27:(Suppl. 1):1995;2-8.
96. Zhang S., Li H., Cheng H. The preventive recurrent results of postoperative intravesical instillation therapy in bladder cancer. Chung Hua Wai Ko Tsa Chih. 33:1995;304.
97. Sekine H., Fukui I., Yamada T., et al. Intravesical mitomycin C and doxorubicin sequential therapy for carcinoma in situ of the bladder: a longer followup result. J. Urol. 151:1994;27-30.
98. Witjes J.A., Caris C.T.M., Mungan N.A., et al. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. J. Urol. 160:1998;1668.
99. Van der Meijden A.P., Hall R.R., Macaluso M.P., et al. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Eur. Urol. 29:1996;199-203.
100. Raitanen M.P., Lukkarinen O. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish multicentre study group. Br. J. Urol. 76:1995;697.
101. Kaasinen E, Wijkström H, Malmström PU, et al. Alternating mitomycin C and BCG instillations versus BCG alone in the treatment of carcinoma in situ of the urinary bladder, A Nordic study. Eur Urol 2003, in press.
102. Obata K., Ohashi Y., Akaza H., et al. Prophylactic chemotherapy with intravesical instillation of adriamycin and oral administration of 5-flourouracil after surgery for superficial bladder cancer. The Japanese Urological cancer research Group for adriamycin. Cancer Chemother. Pharmacol. 35:(Suppl.):1994;88-92.
103. Mukamel E., DeKernion J.B. Conservative treatment of diffuse carcinoma in situ of the bladder with repeated courses of intravesical therapy. Br. J. Urol. 64:1989;143.
104. Prout G.R. Jr, Griffin P.P., Nocks B.N., et al. Intravesical therapy of low stage bladder carcinoma with mitomycin C: comparison of results in untreated and previously treated patients. J. Urol. 127:1982;1096.
105. Issel B.F., Prout G.R., Soloway M.S., et al. Mitomycin C intravesical therapy in noninvasive bladder cancer after failure on thiotepa. Cancer. 53:1984;1025.
106. Milani C., Bassi P., Meneghini A., et al. Mitomycin C in multiple superficial bladder tumors short term therapy long term results. Urol. Int. 48:1992;154.
107. Smith J.A. Jr, Labasky R.F., Cockett A.T., Fracchia J.A., Montie J.E., Rowland R.G. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J. Urol. 162:1999;1697-1701.
108. Oosterlinck W, Lobel B, Malmström PU, Stöckle M, Sternberg U. EAU guidelines on urinary bladder cancer 2000, Eur Urol 2002;41:105-12.
109. de vere White R.W., Ditch A., Tesluk H., et al. Prognostic significance of DNA ploidy in Ta/T1 bladder cancer: a southwest oncology group study. Urol. Oncol. 2:1996;27.
110. Lee E., Park I., Lee C. Prognostic markers of intravesical Bacillus Calmette-Guerin therapy for multiple, high-grade, stage T1 bladder cancers. Int. J. Urol. 4:1997;552.
111. Lebret T., Becette V., Barbagelatta M., et al. Correlation between p53 overexpression and response to Bacillus Calmette-Guerin therapy in a high risk select population of patients with T1G3 bladder cancer. J. Urol. 159:1998;788.
112. Oveson H., Horn T., Steven K. Long term efficacy of intravesical Bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J. Urol. 157:1997;1655.
113. Walther M.M., Figg W.D., Linehan W.M. Intravesical surimin: a novel agent for the treatment of superficial transitional-cell carcinoma of the bladder. World J. Urol. 14:1996;S8-11.
114. Au J.L., Kalns K., Gan Y., et al. Pharmacologic effects of paclitaxel in human bladder tumors. Cancer Chemother. Pharmacol. 41:1997;69.
115. Nativ O., Aronson M., Medalia O., et al. Antineoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int. J. Cancer. 70:1997;297.
116. Song D., Wientejes M.G., Au J.L. Bladder tissue pharmacokinetics of intravesical taxol. Cancer Chemother. Pharmacol. 40:1997;285.
117. Pu Y.S., Hsieh T.S., Cheng A.L., et al. Combined cytotoxic effects of tamoxifen and chemotherapeutic agents on bladder cancer cells: a potential use in intravesical chemotherapy. Br. J. Urol. 77:1996;76.
118. Witjes W.P., Konig M., Boeminghaus F.P., et al. Results of a European comparative randomized study comparing oral bropirimine vs. intravesical BCG treatment in BCG-naïve patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. Eur. Urol. 36:1999;576-581.
119. Erlichman C., Vidgen D., Wu A. Antineoplastic drug cytotoxicity in a human bladder cancer cell line: implications for intravesical chemotherapy. Urol. Res. 15:1987;13.
120. Nygren P., Csoka K., Larsson R., Busch C., Wester K., Malmström P.U. Activity of standard and investigational cytotoxic drugs in primary cultures of tumor cells from patients with kidney and urinary bladder carcinomas. J. Urol. 162:1999;2200-2204.
121. Schmittgen T.D., Weaver J.M., Badalament R.A., et al. Correlation of human bladder tumor histoculture proliferation and sensitivity to mitomycin C with tumor pathobiology. J. Urol. 152:1994;1632.
122. Nagawa M., Emoto A., Nasu N., et al. Clinical significance of multi-drug resistance associated protein and P-glycoprotein in patients with bladder cancer (see comments). J. Urol. 157:1997;1260.
123. Nargund V.H., Lowe J., Flannigan G.M., et al. Role of P-glycoprotein in chemoresistant superficial bladder tumors. Eur. Urol. 31:1997;160.
124. Long J.P. Jr, Prout G.R. Jr, Wong Y.K., et al. The effect of verapamil on a multi-drug resistant bladder carcinoma cell line and its potential as an intravesical chemotherapeutic agent. J. Urol. 143:1990;1053.
125. Duffy P.M., Hayes M.C., Gatrell S.K., et al. Determination and reversal of resistance to epirubicin intravesical chemotherapy. Br. J. Urol. 77:1996;824.
126. Naito S., Kotoh S., Omoto T., et al. Prophylactic intravesical instillation chemotherapy against recurrence after a transurethral resection of superficial bladder cancer: a randomized controlled trial of doxorubicin plus verapamil versus doxorubicin alone. The Kyushu University Urological Oncology Group. Cancer Chemother. Pharmacol. 42:1998;367.
127. Yu D.S., Chu T.M., Yeh M.Y., Chang S.Y., Ma C.P., Han S.H. Antitumor activity of doxorubicin-monoclonal antibody conjugate on human bladder cancer. J. Urol. 140:1988;415.
128. Tanaka J., Sato E., Saito Y., et al. Preparation of a conjugate of mitomycin C and anti-neural cell adhesion molecule monoclonal antibody for specific chemotherapy against biliary tract carcinoma. Surg. Today. 28:1998;1217.
129. Hashimoto H., Tokunaka S., Sasaki M., et al. Dimethylsulfoxide enhances the absolution of chemotherapeutic drug instilled into the bladder. Urol. Res. 20:1992;233.
130. Walker L., Walker M.C., Parris C.N., Masters J.R. Intravesical chemotherapy: combination with dimethyl sulfoxide does not enhance cytotoxicity in vitro. Urol. Res. 16:1988;329.
131. Ohtani M., Miyanaga N., Naguchi R., et al. Promotive effects of intravesical instillation of dimethylsulfoxide on bladder carcinogenesis in mice. Nippon Hinyokika Gakkai Zasshi. 83:1992;1423.
132. Parris C.N., Masters J.R., Walker M.C., Newman B., Riddle P. Intravesical chemotherapy: combination with Tween 80 increases cytotoxicity in vitro. Urol. Res. 15:1987;17.
133. Masters J.R., McDermott B.J., Jenkins W.E., et al. Thiotepa pharmacokinetics during intravesical chemotherapy and the influence of Tween 80. Cancer Chemother. Pharmacol. 25:1990;267.
134. Maier U., Baumgartner G. Metaphylactic effect of mitomycin C with and without hyal-uronidase after transurethral resection of bladder cancer: randomized trial. J. Urol. 141:1989;529.
135. Brausi M., Campo B., Pizzocaro G., et al. Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study. Urology. 51:1998;506.
136. Rigatti P., Lev A., Colombo R. Combined intravesical chemotherapy with mitomycin-C and local bladder microwave-induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. Eur. Urol. 20:1991;204.
137. Colombo R., Da Pozzo L.F., Lev A., et al. Neoadjuvant combined microwave induced hyperthermia and topical chemotherapy alone for superficial bladder cancer. J. Urol. 155:1996;1227.
138. Miyake H., Hara I., Gohji K., et al. Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer. Anticancer Res. 18:1998;3087.
139. Loskog A., Bjorkland A., Brown M.P., Korsgren Q., Malmström P.U., Tötterman T.H. Potent antitumor effects of CD154 transduced tumor cells in experimental bladder cancer. J. Urol. 166:2001;1093-1097.